UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

Form 6-K

 

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

 

For the month of April 2021

Commission File Number: 001-40106

 

4D pharma plc

(Translation of Registrant’s name into English)

 

5th Floor, 9 Bond Court

Leeds

LS1 2JZ

United Kingdom

Tel: +44 (0) 113 895 013

(Address of principal executive offices)

 

 

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [X] Form 40-F [  ]

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

 

 

 

 
 

 

Announcement of Annual Report and Annual General Meeting

 

On April 15, 2021, 4D pharma plc (the “Company”) issued a press release to announce that the Annual Report for the year ended December 31, 2020 (the “Annual Report”) and the notice of the Company’s Annual General Meeting (“Notice of AGM”) have been posted to shareholders. The AGM will be held on Monday, May 24, 2021 at 10:00 am (British Summer Time) at the Company’s offices at 9 Bond Court, Leeds LS1 2JZ. Electronic copies of both the Annual Report and Notice of AGM can be found on the Company’s website at www.4dpharmaplc.com.

 

A copy of the press release is attached as Exhibit 99.1 to this current report on Form 6-K and is incorporated by reference herein.

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  4D pharma plc
   
Date: April 16, 2021 /s/ Duncan Peyton
  Duncan Peyton
  Chief Executive Officer

 

 
 

 

INDEX TO EXHIBITS

 

Exhibit    
Number   Exhibit Title
     
99.1   Press Release, dated April 15, 2021.

 

 

 

 

Exhibit 99.1

 

 

4D pharma PLC

 

4D pharma plc

 

(the “Company” or “4D”)

 

Annual Report and Notice of AGM

 

Leeds, UK, April 15, 2021 – 4D pharma plc (AIM: DDDD, NASDAQ, LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announces that the Annual Report and Accounts for the year to 31 December 2020 (the “Annual Report”) and the notice of the Company’s Annual General Meeting (“Notice of AGM”) have been posted to shareholders.

 

Electronic copies of both the Annual Report and the Notice of AGM are now available on the Company’s website, www.4dpharmaplc.com.

 

The AGM will be held on Monday 24 May 2021 at 10:00 a.m. (British Summer Time) at the Company’s offices, 9 Bond Court, Leeds LS1 2JZ.

 

About 4D pharma

 

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease.  4D has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

 

4D pharma’s Live Biotherapeutic products (LBPs) are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical programs, namely a Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, a Phase I/II study of MRx-4DP0004 in asthma, a Phase II study of MRx-4DP0004 in patients hospitalized with COVID-19, and Blautix® in Irritable Bowel Syndrome (IBS) which has completed a successful Phase II trial. Preclinical-stage programs include candidates for CNS disease such as Parkinson’s disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

 

For more information, refer to https://www.4dpharmaplc.com

 

 
 

 

 

4D pharma PLC

 

Contact Information:

 

4D pharma

Investor Relations: ir@4dpharmaplc.com

 

N+1 Singer - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / Iqra Amin / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

 

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson / Phil Walker

 

Stern Investor Relations, Inc. +1-212-362-1200

Julie Seidel Julie.seidel@sternir.com

 

Image Box Communications +44 (0)20 8943 4685

Neil Hunter / Michelle Boxall

neil@ibcomms.agency / michelle@ibcomms.agency